ADC Therapeutics (ADCT) Free Cash Flow (2020 - 2026)

ADC Therapeutics (ADCT) has reported Free Cash Flow for 7 consecutive years, with -$29.7 million the latest figure, recorded in Q1 2026.

• Quarterly Free Cash Flow rose 47.45% year-over-year to -$29.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$114.6 million (up 16.16% YoY) and the FY2025 annual result came in at -$141.4 million, down 13.42% from the prior year.
• Free Cash Flow improved to -$29.7 million in Q1 2026 per ADCT's latest filing, from -$31.1 million in the prior quarter.
• Over the last five years, Free Cash Flow for ADCT reached as high as $2.0 million in Q3 2022 and fell as low as -$56.6 million in Q1 2025.
• A 5-year average of -$32.8 million and a median of -$32.0 million in 2023 frame the typical range for Free Cash Flow.
• Annual changes were most pronounced in 2022 — Free Cash Flow jumped 103.34% — and 2023, when it tumbled 1965.77%.
• Year by year, Free Cash Flow stood at -$53.8 million in 2022, then soared by 40.63% to -$32.0 million in 2023, then surged by 31.35% to -$21.9 million in 2024, then plunged by 41.84% to -$31.1 million in 2025, then advanced by 4.44% to -$29.7 million in 2026.
• According to Business Quant data, Free Cash Flow over the past three periods registered -$29.7 million, -$31.1 million, and -$29.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.